iShares 0 3 Month Treasury Bond ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.7 (market cap $2.27B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 50.4× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| SGOV | SLS | |
|---|---|---|
Market Cap | $114.40B | $2.27B |
Volume | 18,879,081 | 4,179,659 |
Sector | Fixed Income | Health |
52-Week High | $100.72 | $15.46 |
52-Week Low | $100.28 | $1.39 |
Typical Hold Time | 50 Days | — |
Enterprise Value | — | $2.14B |
Signals from Pluang's Aura AI — not financial advice
SGOV trades at $100.51 with minimal daily movement (+0.04%), reflecting its stable Treasury bond ETF nature. Technical indicators show bearish momentum with oversold RSI readings, while fundamental data remains limited for this short-term Treasury fund. Recent institutional selling by Envestnet Asset Management indicates some professional caution, though the fund continues regular dividend distributions.
The outlook remains stable given SGOV's short-term Treasury focus, though rising bond yields present both opportunity and risk. Investors benefit from monthly dividends but face interest rate sensitivity. Current technical weakness suggests potential near-term pressure despite the fund's defensive characteristics in volatile markets.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →